SmallCapReview.com is a leading small cap and penny stock site since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Elysium Internet (Pinksheets: EYSM) $0.04. Today announced that it has launched a new local Chiropractor directory under its recently acquired brand http://www.chiropractor.net/. The Chiropractic market in the United States alone is estimated to be worth $7 billion a year.
Elysium CEO Scott Gallagher, stated, "Today we take another step towards our goal of becoming the leader in local advertising for small and medium sized US based businesses by expanding our performance based business into the $7 billion US Chiropractic market. We estimate that more than half of the roughly 60,000 chiropractors in the US are self employed with 3 or less employees. These businesses, as well as larger practices, will greatly benefit from our performance based model that has already generated thousands of appointments for Podiatrists, Dietitians and Therapists all over the country during 2009."
Gallagher continued, "We expect the launch of Chiropractor. net to have a positive impact on both revenue and earnings during Q1 and the full year of 2010 as we aggressively expand the size of our target market and build on the gains of Podiatrists.com. We're continuing discussions taking an opportunistic approach to the current market regarding additional acquisitions of synergistic Internet brands and properties that will help position us as the leader in local advertising and online media."
What They Do: Elysium Internet (EYSM) is a publicly traded direct navigation Internet media Company. EYSM is focused on building targeted industry specific direct navigation based Internet directories and portals that generate significant traffic for the benefit of its advertising partners. The Company uses an ad based subscription model to generate the majority of its revenue.
Elysium operates through a network of 15 Internet Properties that generate millions of page view’s annually. Due to the extremely high quality of Elysium’s domain portfolio the vast amount of the traffic generated by the network properties is organic or non-paid traffic.
Elysium CEO Scott Gallagher, stated, "Today we take another step towards our goal of becoming the leader in local advertising for small and medium sized US based businesses by expanding our performance based business into the $7 billion US Chiropractic market. We estimate that more than half of the roughly 60,000 chiropractors in the US are self employed with 3 or less employees. These businesses, as well as larger practices, will greatly benefit from our performance based model that has already generated thousands of appointments for Podiatrists, Dietitians and Therapists all over the country during 2009."
Vishay Intertechnology (NYSE: VSH) $7.54. Today announced that fourth quarter revenues will be above the company's previous outlook. Vishay now expects fourth quarter revenues to be in the range of $580 to $600 million. The previous outlook provided on October 27, 2009 was for revenues of $530 to $570 million.
What They Do: Vishay Intertechnology, Inc., a Fortune 1,000 Company listed on the NYSE (VSH), is one of the world's largest manufacturers of discrete semiconductors (diodes, rectifiers, MOSFETs, optoelectronics, and selected ICs) and passive electronic components (resistors, capacitors, inductors, sensors, and transducers).
Isis Pharmaceuticals (Nasdaq: ISIS) $9.94. Today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer. Teva and OncoGenex will collaborate on a global Phase 3 clinical program for OGX-011 in patients with prostate and non-small cell lung cancer.
What They Do: Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.
IMAX Corporation (Nasdaq: iMAX) $12.54. Today announced along with Twentieth Century Fox that that James Cameron's Avatar grossed a record breaking $9.5 million from 178 IMAX(R) theatres domestically from December 18 through December 20, 2009, registering approximately 13% of the film's total domestic gross of $73 million on less than 3% of the screens.
What They Do: IMAX Corporation is one of the world's leading entertainment technology companies, specializing in immersive motion picture technologies.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview. SmallCapReview has been compensated three thousand dollars by a third party GreenHorseshoe for its efforts with regards to Elysium Internet
